FMP

FMP

Enter

NYMX - Nymox Pharmaceutical...

Financial Summary of Nymox Pharmaceutical Corporation(NYMX), Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and developme

photo-url-https://financialmodelingprep.com/image-stock/NYMX.png

Nymox Pharmaceutical Corporation

NYMX

NASDAQ

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

0.2 USD

-0.0001 (-0.05003%)

About

ceo

Dr. Paul Averback DABP, M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physician...

CIK

0001018735

ISIN

BSP733981026

CUSIP

P73398102

Address

Bay & Deveaux Streets

Phone

18009369669

Country

BS

Employee

3

IPO Date

Nov 26, 1997

Summary

CIK

0001018735

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

P73398102

ISIN

BSP733981026

Country

BS

Price

0.2

Beta

0.82

Volume Avg.

134.78k

Market Cap

18.24M

Shares

-

52-Week

0.17-0.74

DCF

1.27

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.86

P/B

-

Website

https://nymox.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest NYMX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep